Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300572899> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- W4300572899 endingPage "7" @default.
- W4300572899 startingPage "33" @default.
- W4300572899 abstract "Sitagliptin and vildagliptin are dipeptidyl peptidase 4 (DPP-4) inhibitors, also known as gliptins. They are approved for use as oral glucose-lowering agents, although they have no proven impact on morbidity or mortality. Their glucose-lowering effect is limited and their long-term risks are poorly documented. A third gliptin, saxagliptin, is now authorised in the European Union for second-line treatment of type 2 diabetes, in combination with metformin, a glucose-lowering sulphonylurea, or a glitazone. Clinical evaluation of saxagliptin is mainly based on 8 double-blind randomised trials in about 5000 patients, including 4 trials of second-line combination therapy (1 non-inferiority trial versus sitagliptin, and 3 placebo-controlled trials). The reduction in the mean HbAlc levels with saxagliptin was about 0.3% to 0.8% (in absolute values) versus placebo, which is similar to that reported with other gliptins. The adverse effect profile of saxagliptin is similar to that of the other gliptins, and includes infections (especially urinary tract and sinus infections), gastrointestinal disorders, musculoskeletal disorders, fatigue, and depression. There also appears to be an increased risk of bone fractures. Potential long-term adverse effects include infectious, cardiac, hepatic, pancreatic and cutaneous disorders. Unlike the other gliptins, saxagliptin is metabolised by the cytochrome P450 isoenzyme CYP 3A4, hence a high potential for pharmacokinetic interactions. The risk-benefit balance of saxagliptin is no better than that of other gliptins, and saxagliptin carries a higher risk of drug interactions. In practice, when metformin or glibenclamide monotherapy fails, it is better to continue with a standard treatment strategy, such as resorting to insulin or abandoning strict glycaemic control." @default.
- W4300572899 created "2022-10-03" @default.
- W4300572899 date "2011-02-01" @default.
- W4300572899 modified "2023-10-18" @default.
- W4300572899 title "Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions." @default.
- W4300572899 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21488586" @default.
- W4300572899 hasPublicationYear "2011" @default.
- W4300572899 type Work @default.
- W4300572899 citedByCount "1" @default.
- W4300572899 countsByYear W43005728992022 @default.
- W4300572899 crossrefType "journal-article" @default.
- W4300572899 hasConcept C126322002 @default.
- W4300572899 hasConcept C134018914 @default.
- W4300572899 hasConcept C197934379 @default.
- W4300572899 hasConcept C2776453732 @default.
- W4300572899 hasConcept C2777180221 @default.
- W4300572899 hasConcept C2778763485 @default.
- W4300572899 hasConcept C2779284873 @default.
- W4300572899 hasConcept C2780282729 @default.
- W4300572899 hasConcept C2780323712 @default.
- W4300572899 hasConcept C555293320 @default.
- W4300572899 hasConcept C71924100 @default.
- W4300572899 hasConcept C98274493 @default.
- W4300572899 hasConceptScore W4300572899C126322002 @default.
- W4300572899 hasConceptScore W4300572899C134018914 @default.
- W4300572899 hasConceptScore W4300572899C197934379 @default.
- W4300572899 hasConceptScore W4300572899C2776453732 @default.
- W4300572899 hasConceptScore W4300572899C2777180221 @default.
- W4300572899 hasConceptScore W4300572899C2778763485 @default.
- W4300572899 hasConceptScore W4300572899C2779284873 @default.
- W4300572899 hasConceptScore W4300572899C2780282729 @default.
- W4300572899 hasConceptScore W4300572899C2780323712 @default.
- W4300572899 hasConceptScore W4300572899C555293320 @default.
- W4300572899 hasConceptScore W4300572899C71924100 @default.
- W4300572899 hasConceptScore W4300572899C98274493 @default.
- W4300572899 hasIssue "113" @default.
- W4300572899 hasLocation W43005728991 @default.
- W4300572899 hasOpenAccess W4300572899 @default.
- W4300572899 hasPrimaryLocation W43005728991 @default.
- W4300572899 hasRelatedWork W1802818529 @default.
- W4300572899 hasRelatedWork W1981713709 @default.
- W4300572899 hasRelatedWork W2022501381 @default.
- W4300572899 hasRelatedWork W2033673890 @default.
- W4300572899 hasRelatedWork W2034574623 @default.
- W4300572899 hasRelatedWork W2073841569 @default.
- W4300572899 hasRelatedWork W2565982028 @default.
- W4300572899 hasRelatedWork W2774449951 @default.
- W4300572899 hasRelatedWork W3119986766 @default.
- W4300572899 hasRelatedWork W3194797831 @default.
- W4300572899 hasVolume "20" @default.
- W4300572899 isParatext "false" @default.
- W4300572899 isRetracted "false" @default.
- W4300572899 workType "article" @default.